HERIZON-GEA-01 Trial Highlights Zymeworks' Path To $440M Milestones And Growth

Zymeworks (ZYME) posts strong Phase 3 Ziihera data in HER2+ GEA and eyes up to $440M in milestones plus royalties—read the ...
pharmaphorum

Hengrui gets first OK for a PD-L1/TGF-beta drug for cancer

Jiangsu Hengrui Pharma has chalked up a first-in-class approval for retlirafusp alfa, a bifunctional drug that targets PD-L1 ...

KAHR Bio Announces Strong Topline Phase 2 Results for DSP107 in Combination with Anti-PD-L1 Therapy in Colorectal Cancer

Company closed $22M financing to support randomized Phase 2b trial; IND cleared and study initiated; Interim results anticipated in late 2026; topline data expected in H2/2027 ...
C&EN

A targeted protein degrader that doubles as a cancer vaccine

The result is one molecule that can be both a checkpoint degrader and a cancer vaccine ( Nature 2026, DOI: 10.1038/s41586-025 ...
ascopubs.org

Real-world data based on PD-L1 expression in early-stage NSCLC in an east-Asian patient population: A 10-year follow-up study.

ctDNA-Lung-DETECT: ctDNA outcomes for resected early stage non-small cell lung cancers at 12 months. Surgical outcomes in patients with non-small cell lung cancer receiving neoadjuvant ...
Fierce Pharma

UPDATED: Jazz touts Ziihera as the new HER2 agent of choice in stomach cancer

Forget about Herceptin. There’s a new HER2 agent that ought to be used in HER2-positive stomach cancer, and that’s Jazz ...